Stockscreener 앱 받기
8.82
3.04%
0.26
시간 외 거래:
8.88
0.06
+0.68%
Immunitybio Inc 주식(IBRX)의 최신 뉴스
After years of delays, new deadline looms in 2028 for drug manufacturing plant in Dunkirk - Buffalo News
Assessing ImmunityBio (IBRX) Valuation After NCCN ANKTIVA Update And NK Cell Therapy Progress - simplywall.st
ImmunityBio Inc Trade Ideas — SWB:26CA - TradingView
ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer - Insider Monkey
ImmunityBio Stock Jumps on Big Cancer Breakthrough - TipRanks
5 Most Buzzing Stocks to Buy with the Highest Upside Potential - Insider Monkey
ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference - MarketBeat
Heights Capital Management Inc. Purchases New Position in ImmunityBio, Inc. $IBRX - MarketBeat
IBRX Stock Rises After NCCN Guideline Update Expands ANKTIVA’s UseRetail Expects Sales To Surge - Stocktwits
Is 28.9% Fall In ImmunityBio (IBRX) Stock A Buying Opportunity? - Trefis
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion - Seeking Alpha
ImmunityBio Stock To $6? - Trefis
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga
NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus - Yahoo Finance
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include AN - PharmiWeb.com
Will Anktiva Remain a Key Factor in ImmunityBio’s Revenue Expansion in 2026? - Bitget
ImmunityBio (NASDAQ:IBRX) Given "Buy" Rating at D. Boral Capital - MarketBeat
Why Is ImmunityBio (IBRX) Stock Jumping Today? ANKTIVA Gains NCCN Backing - Tokenist
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026? - TradingView
IBRX Stock Is Rising Pre-Market On This Cancer Treatment Expansion - Stocktwits
ImmunityBio gains on NCCN guidelines update (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have been updated to officially include Anktiva (generic name: N-803) in combination with BCG as a treat - Bitget
Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA - Business Wire
IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins - Stocktwits
ImmunityBio (NASDAQ:IBRX) Stock Price Down 2.1%Here's What Happened - MarketBeat
ImmunityBio rises after updates on cell therapy programs - MSN
IBRX Stock Jumps on Progress in NK Cell Therapy Production - Yahoo Finance
Is ImmunityBio, Inc. (IBRX) a good stock to buy now? - MSN
Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now? - Insider Monkey
Earnings call transcript: ImmunityBio’s Q4 2025 EPS beats forecast, stock surges - Investing.com Nigeria
ImmunityBio resubmits bladder cancer application to FDA By Investing.com - Investing.com Nigeria
ImmunityBio (IBRX) climbs 7.3% as firm nears development of 'world bank of NK cells' - MSN
BTIG Research Upgrades ImmunityBio (NASDAQ:IBRX) to "Strong-Buy" - MarketBeat
ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells’ - Insider Monkey
Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge - Yahoo Finance
ImmunityBio’s European Expansion Boosts Market Reach - timothysykes.com
ImmunityBio (NASDAQ:IBRX) Stock Price Up 7.3%Time to Buy? - MarketBeat
IBRX Stock Rises 9%: ImmunityBio Reports Breakthrough In NK Cell Therapy Production - Stocktwits
ImmunityBio’s Market Expansion Amidst Financial Challenges - StocksToTrade
IBRX Stock: Anktiva Receives Approvals and Future Steps Ahead - Bitget
ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus - TechStock²
IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking - Yahoo Finance
ImmunityBio Valuation: Paying 33x Sales for Anktiva - TradingView
IBRX Stock: Anktiva's Approvals and What Comes Next - Yahoo Finance
ImmunityBio Expands Reach with European Approval, IBRX Stock Gains Momentum - timothysykes.com
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell? - sharewise.com
ImmunityBio (NASDAQ:IBRX) Shares Gap UpWhat's Next? - MarketBeat
ImmunityBio Shares Surge 295% Year-to-Date: Should You Buy, Hold, or Sell? - Bitget
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 - PharmiWeb.com
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors - Investing News Network
Why ImmunityBio Stock Is Soaring Today - AOL.com
Why Is ImmunityBio Stock Soaring On Friday? - Benzinga
IMMUNITYBIO, INC. (IBRX) - MSN
1.20%
0.06%
자본화:
|
볼륨(24시간):